Oxaprozin - patents, research & applications

55,757Patents

230Research papers228 indexed in detail

4,439Patents - last 3 years

8Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#	Assignee	Patents
1	Merck and Co Inc	2,175
2	AbbVie Inc	1,610
3	Pfizer Inc	1,029
4	Roche Holding AG	996
5	Bristol Myers Squibb Co	773

6	Procter and Gamble Co	764
7	Abbott Laboratories	686
8	Amgen Inc	682
9	Purdue Pharma LP	657
10	Takeda Pharmaceutical Co Ltd	533

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#	Code	Area	Patents
1	`A61P`	Therapeutic activity (drug indications)	42,898
2	`A61K`	Medicinal preparations	40,862
3	`C07D`	Heterocyclic compounds	19,362
4	`C07K`	Peptides	9,021
5	`Y02A`	Climate change adaptation	4,246

6	`C07C`	Acyclic and carbocyclic compounds	3,602
7	`C12N`	Microorganisms, enzymes	3,526
8	`G01N`	Investigating / analysing materials	3,100
9	`A61L`	Sterilising / disinfecting materials	2,749
10	`A61Q`	Cosmetics, personal care	2,377

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Representative patents

The filings that best characterise the patent activity around this compound, most-referenced first.

Title	Year	Assignee	Cited by
Potassium, sodium and tris oxaprozin salt pharmaceutical formulations	2000	Pfizer Inc	9
Oxaprozin calcium salt	1984	Pfizer Inc	7
Oxaprozin calcium salt pharmaceutical compositions	1985	Pfizer Inc	6
Oxaprozin or closely related compound for the treatment and prevention of pruritus	2006		3
Oxaprozin and preparation technology thereof	2012		2

How research activity has moved

Papers published per year for this compound, over the last decade of indexed records.

Year	Papers
2016	6
2017	3
2018	1
2019	13
2020	6
2021	6
2022	9
2023	7
2024	1

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#	Author	Affiliation	Papers
1	Hans W. Ruelius	University of Pennsylvania	6
2	Matthew D. Hall	National Institutes of Health	5
3	P. Mura	University of Florence	5
4	Jerome A. Hubsher	Penn Center for AIDS Research	5
5	Rita Matlis	Tufts Medical Center	4

6	Natascia Mennini	University of Florence	4
7	Patricia Dranchak	National Center for Advancing Translational Sciences	4
8	Marzia Cirri	University of Florence	4
9	Francesca Maestrelli	University of Florence	4
10	Barry R. Walker	University of Pennsylvania	4

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Title	Year	Cited by	Topic
The “High Solubility” Definition of the Current FDA Guidance on Biopharmaceutical Classification System May Be Too Strict for Acidic Drugs	2004	287	Drug Solubulity and Delivery Systems
In vitro scavenging activity for reactive oxygen and nitrogen species by nonsteroidal anti-inflammatory indole, pyrrole, and oxazole derivative drugs	2004	174	Inflammatory mediators and NSAID effects
Pulmonary response to surface‐coated nanotitanium dioxide particles includes induction of acute phase response genes, inflammatory cascades, and changes in microRNAs: A toxicogenomic study	2011	168	MicroRNA in disease regulation
Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells	1998	118	Inflammatory mediators and NSAID effects
The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective.	2003	93	Inflammatory mediators and NSAID effects

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular formula and structure of oxaprozin?

Oxaprozin has the molecular formula C18H15NO3 with a molecular weight of 293.322. Its canonical chemical name is 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid, indicating a propanoic acid moiety attached to a diphenyl-substituted oxazole ring system.

Which pharmaceutical companies hold the most patents involving oxaprozin?

The leading patent assignees for oxaprozin-related inventions are Merck and Co Inc with 2,175 patents, AbbVie Inc with 1,610 patents, and Pfizer Inc with 1,029 patents. Pfizer Inc is notably the assignee of foundational oxaprozin formulation patents including those covering oxaprozin calcium salt and potassium, sodium and tris oxaprozin salt pharmaceutical formulations.

What are the key research topics associated with oxaprozin in academic literature?

Published research on oxaprozin focuses on several topics including drug solubility and delivery systems, cyclooxygenase inhibition and NSAID effects on inflammatory mediators, and adverse effects such as Stevens-Johnson syndrome associated with nonsteroidal antiinflammatory drugs. Studies have examined oxaprozin's in vitro scavenging activity for reactive oxygen and nitrogen species and compared its cyclooxygenase-1 and -2 inhibitory activities.

How has publication activity on oxaprozin changed over time?

Academic publication activity on oxaprozin has been variable, with peak years in 2019 (13 papers) and 2023 (7 papers), but generally modest levels of research output. The 230 papers identified represent cumulative coverage of oxaprozin-related research across the literature.

What alternative pharmaceutical formulations of oxaprozin have been developed?

Patent literature documents multiple salt formulations of oxaprozin designed to improve pharmaceutical properties. These include oxaprozin calcium salt formulations and potassium, sodium, and tris oxaprozin salt formulations. Additionally, patents describe its use in treating and preventing pruritus, demonstrating expanded therapeutic applications beyond traditional NSAID use.